Multi-armored allogeneic MUC1 CAR T cells enhance efficacy and safety in triple-negative breast cancer
Piril Erler(Cellectis (United States)), Beatriz Aranda-Orgillés(Intellicell Biosciences (United States))
Cited by 33
Related Papers
Preclinical Evidence of an Allogeneic Dual CD20xCD22 CAR to Target a Broad Spectrum of Patients with B-cell Malignancies
|Cancer Immunology Research|2023|9